Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Receptor Partners, LLC is a venture capital firm based in New York, established to invest in the future of psychedelic medicine. Founded in 2021, the firm focuses on companies developing innovative therapeutic solutions within the psychedelic treatment ecosystem. Receptor Partners is particularly interested in ventures that address neurological and psychiatric disorders through regulated psychedelic or psychedelic-inspired therapeutics.
The firm currently manages a portfolio that includes eight companies, indicating a commitment to advancing the field of psychedelic medicine. Receptor Partners aims to support teams pioneering new approaches to drug discovery and delivery, leveraging its expertise in navigating the complex landscape of psychedelic treatments.
As of now, Receptor Partners has not disclosed specific fund sizes or assets under management (AUM). However, their focus on early-stage investments suggests a strategy aimed at nurturing startups through their critical growth phases. The firm operates primarily in North America and Europe, targeting innovative companies that align with their investment thesis.
Receptor Partners invests in the psychedelic medicine sector, specifically targeting companies that are developing regulated psychedelic or psychedelic-inspired therapeutics. Their investment strategy encompasses early-stage ventures, including those in the Friends & Family, Accelerator/Incubator, Seed, and Series A stages. The firm is particularly interested in companies focused on central nervous system (CNS) drug discovery and mental health biotechnology.
The firm seeks to support innovative drug delivery systems and therapeutic solutions that address critical challenges in the field. Receptor Partners emphasizes the importance of differentiated therapeutic solutions, particularly those that can navigate regulatory pathways effectively. Founders with a strong scientific foundation, defensible intellectual property, and a credible regulatory strategy are likely to align well with Receptor's investment criteria.
Receptor Partners has built a notable portfolio of companies within the psychedelic medicine sector. The following companies are part of their investment roster:
This diverse portfolio reflects Receptor Partners' commitment to supporting innovative solutions in the mental health space, particularly through the lens of psychedelic medicine.
Zack Sherman - General Partner/Founder. Zack has a background in venture capital and has been involved in the psychedelic medicine space for several years. He previously served as a founder and general partner at Receptor, emphasizing his expertise in drug delivery and regulatory pathways.
To pitch Receptor Partners, founders should visit their website at receptor.vc. It is recommended to include a comprehensive overview of the startup's scientific foundation, regulatory strategy, and market potential in the pitch deck. While specific response time expectations are not disclosed, founders should anticipate a thorough review process given the firm's specialized focus.
Warm introductions may enhance the chances of securing a meeting, particularly from individuals within the psychedelic medicine community or related sectors.
As of the latest updates, there have been no recent public announcements or investments reported by Receptor Partners since 2021. The firm was noted for participating in the oversubscribed seed financing of Mycrodose Therapeutics in September 2021, highlighting their active role in the psychedelic medicine investment landscape during that period.
What types of companies does Receptor Partners invest in?
Receptor Partners focuses on companies developing regulated psychedelic or psychedelic-inspired therapeutics, particularly in the areas of CNS drug discovery and mental health biotechnology.
What stages of investment does Receptor Partners target?
The firm invests in early-stage companies, including those in the Friends & Family, Accelerator/Incubator, Seed, and Series A stages.
How can I pitch my startup to Receptor Partners?
Founders can submit their pitches through the firm's website at receptor.vc. It is advisable to include detailed information about the scientific foundation and regulatory strategy of your project.
What makes Receptor Partners different from other venture capital firms?
Receptor Partners specializes exclusively in the psychedelic medicine sector, providing strategic guidance and support tailored to the unique challenges of this field.
What geographic areas does Receptor Partners focus on?
The firm primarily targets companies based in North America and Europe, reflecting a broad interest in the global psychedelic medicine landscape.
What is the typical check size for investments?
Receptor Partners has not disclosed specific check sizes, but they focus on early-stage investments, which typically range from seed funding to Series A rounds.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.